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Abstract
Purpose 18F-Florbetapir has been reported to show cardiac uptake in patients with systemic light-chain amyloidosis (AL).
This study systematically assessed uptake of 18F-florbetapir in patients with proven systemic amyloidosis at sites outside
the heart.
Methods Seventeen patients with proven cardiac amyloidosis underwent 18F-florbetapir PET/CT imaging, 15 with AL and 2
with transthyretin amyloidosis (ATTR). Three patients had repeat scans. All patients had protocolized assessment at the UK
National Amyloidosis Centre including imaging with 123I-serum amyloid P component (SAP). 18F-Florbetapir images were
assessed for areas of increased tracer accumulation and time–uptake curves in terms of standardized uptake values (SUVmean)
were produced.
Results All 17 patients showed 18F-florbetapir uptake at one or more extracardiac sites. Uptake was seen in the spleen in 6
patients (35%; 6 of 9, 67%, with splenic involvement on 123I-SAP scintigraphy), in the fat in 11 (65%), in the tongue in 8 (47%),
in the parotids in 8 (47%), in the masticatory muscles in 7 (41%), in the lungs in 3 (18%), and in the kidney in 2 (12%) on the late
half-body images. The 18F-florbetapir spleen retention index (SRI) was calculated. SRI >0.045 had 100% sensitivity/sensitivity
(in relation to 123I-SAP splenic uptake, the current standard) in detecting splenic amyloid on dynamic imaging and a sensitivity of
66.7% and a specificity of 100% on the late half-body images. Intense lung uptake was seen in three patients, one of whom had
lung interstitial infiltration suggestive of amyloid deposition on previous high-resolution CT. Repeat imaging showed a stable
appearance in all three patients suggesting no early impact of treatment response.
Conclusion 18F-Florbetapir PET/CT is a promising tool for the detection of extracardiac sites of amyloid deposition. The
combination of uptake in the heart and uptake in the spleen on 18F-florbetapir PET/CT, a hallmark of AL, suggests that this
tracer holds promise as a screening tool for AL.
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Introduction
Amyloidoses are a group of diseases in which misfolded pro-
teins are deposited in tissues/organs in a highly aggregated
form as amyloid fibrils, leading to multisystem disease.
About 30 such proteins have been reported to cause human
disease, with the two most common types of systemic amy-
loidosis being transthyretin amyloidosis (ATTR) and acquired
monoclonal immunoglobulin light-chain amyloidosis (AL).
Age-related ATTR (ATTRwt) occurs due to wild transthyretin
protein deposition in the heart, and is an increasingly recog-
nized entity in the elderly. Systemic AL occurs due to an
underlying plasma cell dyscrasia secreting an unstable immu-
noglobulin free light chain. AL is the commonest type of
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amyloidosis. Appropriate treatment is dependent on accurate
identification of the amyloid fibril type and assessment of the
disease extent (particularly in the heart) to allow a risk adapted
treatment strategy [1, 2].
Imaging of amyloid deposits is challenging and progress
has been very slow. Since cardiac involvement is the main
cause of morbidity and mortality, focus has been on cardiac
imaging. Various modalities including echocardiography (the
gold standard for many years), cardiac magnetic resonance
imaging (an emerging gold standard) [3, 4], 99mTc-labelled
3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD)
scintigraphy and 99mTc-labelled pyrophosphate (99mTc-PYP)
scintigraphy [5] for ATTR cardiac amyloid imaging have
become part of routine practice. However, the disease bur-
den in amyloidosis is systemic and imaging other organ
systems has not generally been possible. Standard
cross-sectional imaging is widely used to document en-
largement of an organ, but is not specific for amyloidosis.
At our centre (and at the University of Groningen),
123I-labelled serum amyloid P component (123I-SAP) scin-
tigraphy [6] has been routinely used for visceral amyloid
imaging. However, the technical complexity of this proce-
dure has limited its wider use outside the current two cen-
tres. 123I-SAP scintigraphy is very sensitive and specific for
evaluating amyloid in large solid organs [7], but it is not
reliable for detecting cardiac involvement. Although SAP
uptake is occasionally evident at other sites, the clinical
significance of this is not known.
More recently PET tracers used in the diagnosis of
Alzheimer’s disease have been used to study cardiac in-
volvement in patients with amyloidosis. The most widely
studied tracer is 11C-Pittsburgh compound B [8–12], but
there i s a lso publ ished l i te ra ture on the use of
18F-florbetapir [13–15] and 18F-florbetaben [16]. Despite
the different tracers and limited numbers of participants in
each of the studies, the technique shows promise and pro-
vides good separation between patients confirmed as hav-
ing cardiac amyloidosis and controls. Although the primary
aim of these studies was to study cardiac involvement, sev-
eral of the papers discussed findings in soft tissue areas
outside the heart. Dorbala et al. [13] demonstrated intense
18F-florbetapir lung uptake in a patient with clinical mani-
festations and CT findings of lung amyloid. Osborne et al.
[15] generated activity curves over the dome of the liver
and found that while the uptake in ATTR patients was sim-
ilar to that in controls, uptake in patients with AL was sig-
nificantly increased. Ezawa et al. [12] found many sites of
extracardiac uptake and a good clinical correlation between
gastric uptake and clinical gastric dysmotillity.
We conducted a study investigating the dynamic uptake of
18F-florbetapir centred on the heart and tracer uptake in the
remainder of the body 1 h after injection of tracer. This report
addresses the uptake of tracer outside the heart.
Materials and methods
Recruitment
Patients were recruited for this prospective study of
18F-florbetapir between September 2016 and June 2017. The
inclusion criteria were as follows:
1. Age ≥40 years
2. Amyloid deposition confirmed on tissue biopsy or
imaging
3. Confirmation of amyloid type by either amyloid fibril
typing on a tissue biopsy or appropriate genetic testing
for mutations (or lack of) in genes for hereditary
amyloidosis
4. Evidence of cardiac amyloidosis defined as any one (or
more) of the following:
(a) Cardiac involvement as defined by the international
amyloidosis consensus criteria (including cardiac
biomarkers)
(b) Cardiac involvement by 99mTc-DPD scintigraphy
(c) Cardiac involvement on cardiac MRI imaging
5. Ability to give informed consent
The exclusion criteria were as follows:
1. Inability to lie flat
2. NYHA grade IV heart failure
3. Pregnant or breastfeeding
4. Unwilling to undergo pregnancy test prior to study (in
women of child-bearing potential)
5. Known allergy to Amyvid
All patients underwent serial protocolized assessment at the
UK National Amyloidosis Centre including full biochemical
tests for organ function and serum free light chain measure-
ment, as well as serum and urine protein electrophoresis and
immunofixation, cardiac biomarker measurement, echocardi-
ography, cardiac MRI (unless contraindicated), 123I-SAP scin-
tigraphy and 99mTc-DPD scintigraphy where indicated. Organ
involvement was defined according to international consensus
criteria [17].
The study was approved by the institutional research ethics
committee and all patients provided written informed consent.
Image acquisition, reconstruction and analysis
Patients underwent list mode dynamic PET imaging for
60 min using a Siemens Biograph PET/CT scanner following
administration of an average of 307 MBq (range 169–
370 MBq) of 18F-florbetapir. The heart was placed in the
centre of the field of view and CT imaging was performed
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over the same area using automatic exposure control (CARE
Dose 4D, CARE kV; Siemens Healthcare) with exposure pa-
rameters of 65 mAs and 120 kV. Following dynamic imaging,
the patient was asked to void and following this a half-body
(skull base to thighs) acquisition was performed (late acquisi-
tion) with 3 min per bed position, overlap 42%, and CT with
exposure parameters as above. The mean time between injec-
tion and the half-body acquisition was 64 min (range 61–
69 min).
Images were iteratively reconstructed (two iterations, 21
subsets) using time of flight information and point spread
function modelling, with 2 mm gaussian postfiltering The
60 min list mode data were reconstructed into 37 frames (12
frames of 5 s each, 6 frames of 10 s each, 4 frames of 30 s
each, 6 frames of 60 s each, 8 frames of 300 s each, and 1
frame of 600 s) replicating the processing method used by
Dorbala et al. [13].
18F-Florbetapir images were assessed by a nuclear medi-
cine consultant for areas of increased tracer accumulation
using a HERMES workstation (HERMES Medical
Solutions) and the maximum standardized uptake value
(SUVmax) in these areas was assessed using a volume of
interest (VOI) of variable size on the late half-body images.
Time uptake curves of mean standardized uptake value
(SUVmean) against time were produced by manually
outlining the left ventricular (LV) myocardium and by placing
spherical VOIs on tissues of interest (VOI diameter was varied
depending on the size of the organ). VOIs were placed on the
dome of the liver, the spleen, the lungs, the bonemarrow in the
T10 vertebra, the shoulder muscle (infraspinatus or deltoid
muscle of the right shoulder) and the axillary fat. Curves were
also produced for the stomach lumen and the wall of the stom-
ach when uptake was seen. VOI placement is shown in the
figure in the Supplementary material. A spleen retention index
(SRI) was calculated as the SUVmean in the spleen VOI from
10 to 30 min divided by the integral of the SUV in a 1 cm
diameter spherical VOI placed on the descending aorta from 0
to 20 min after injection.
All available 123I-SAP images were scored for uptake in the
liver, spleen, kidneys and bone marrow by an experienced
amyloid consultant using a four-point scale (0–3) and all
99mTc-DPD images were scored for uptake according to the
grading system of Perugini et al. [18]. Normal tracer distribu-
tions were inferred from the existing literature [19] and from
visual analysis of tracer distribution in our cohort of 17 pa-
tients and 20 scans. All scans were first reviewed after com-
pletion then reviewed again at the end of the study. Briefly, we
considered uptake in the following organs to be physiological
on the half-body images obtained at an average of 64min after
injection: low to moderate uptake (SUVmax 4–8) in the liver,
low-grade uptake (SUVmax 3–4) in the bone marrow, intense
uptake in the small bowel and gallbladder related to physio-
logical excretion of tracer, very low-grade bilateral and
symmetrical uptake (SUVmax <3) in the parotids (seen fre-
quently), and low-grade diffuse uptake (SUVmax 3–4) in the
tongue (also seen frequently). Uptake at all other sites was pre-
sumed to be abnormal and to be related to amyloid deposition.
Results
Seventeen patients were enrolled in the study, of whom 15 had
AL and two had ATTR. Two patients were treatment-naive,
one patient was scanned 2 days after the first cycle of chemo-
therapy and one patient was scanned 9 days after the first cycle
of chemotherapy. The patient demographics are summarized
in Table 1. Two patients had repeat scans following chemo-
therapy treatment (one was scanned just under 7 months after
completion of chemotherapy and the other was still undergo-
ing chemotherapy but had achieved a complete response).
One patient underwent repeat scanning to assess the stability
of unexpected lung uptake. All patients showed uptake in the
heart as reported previously by others [13–15] and these pa-
tients will the subject of a separate article.
All 17 patients showed uptake at one or more extracardiac
sites. Representative late half-body images of areas of
18F-florbetapir uptake are shown as anterior maximum inten-
sity projections with corresponding 123I-SAP images for com-
parison in Fig. 1 and transaxial fused PET/CT images in
Fig. 2. Physiological uptake can be seen in the hepatobiliary
system in all patients. Common sites of uptake were fat, pa-
rotids, tongue, masticating muscles, spleen and bone marrow.
Increased uptake in extracardiac organs seen on the late
half-body images is summarized for each patient in Table 2
(along with respective uptake on 123I-SAP scintigraphy up-
take in liver, spleen, kidneys and bone marrow). Since
18F-florbetapir is excreted through the liver, biliary duct and
small bowel, uptake in these sites is not included.
Spleen uptake
Spleen uptake (Figs. 1b and 2I) was assessed by splenic re-
tention on dynamic imaging as well as on the late half-body
images and compared with spleen uptake using 123I-SAP im-
aging (which is the only imaging modality showing spleen
uptake in amyloidosis). In patients who had a negative
123I-SAP scan (spleen score 0), the spleen curve peaked sharp-
ly during the first 2–3 min, but the SUV fell to background
levels by 10–15 min as shown in Fig. 3a. The plot of SRI
against 123I-SAP visual score is presented in Fig. 3b. All nine
patients with splenic uptake on 123I-SAP scintigraphy (spleen
score >0) had SRIs of >0.045. Using dynamic imaging and
a SRI threshold of 0.045, with 123I-SAP as the reference,
18F-florbetapir had a sensitivity and specificity of 100% for
detecting splenic amyloid deposits. However, on the late
half-body images spleen uptake was only seen in six of the
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nine patients with spleen uptake on 123I-SAP imaging
(Table 2), leading to a specificity of 100% for splenic amyloid
identification but a sensitivity of only 66.7% for late half-body
imaging with 18F-florbetapir. The one third reduction in
specificity suggests that the timing of spleen uptake imaging
by 18F-florbetapir is critical for optimal utility of the scans.
Neither of the two patients with ATTR had spleen uptake of
123I-SAP or 18F-florbetapir.
Fig. 1 Representative half-body
maximum intensity projection
18F-florbetapir anterior views
(a–c) with corresponding 123I-
SAP planar images for compari-
son (d–f): a 18F-florbetapir lung
uptake (patient 3), b 18F-
florbetapir uptake in the heart,
thyroid and spleen (patient 14), c
18F-florbetapir uptake in the
tongue and heart (patient 17),
d 123I-SAP uptake in the liver
(patient 3; all other uptake is in the
blood pool), e 123I-SAP uptake in
the liver and spleen (patient 14),
f 123I-SAP uptake in the stomach
(this is a frequent appearance with
123I-labelled tracers and is not an
indicator of amyloid deposition).
Physiological 18F-florbetapir
uptake can be seen in the
hepatobiliary system of all
patients
Table 1 Patient demographics
and clinical history Patient Age (years) Sex Diagnosis
1a 80 F AL, cardiac, renal, liver, splenic involvement
2 46 F AL, cardiac, renal, splenic involvement
3a 61 M AL, cardiac, soft tissue involvement, mild macroglossia
4 68 M AL, cardiac, soft tissue involvement, macroglossia
5 50 M AL, cardiac, liver, splenic, bone marrow involvement, macroglossia,
underlying myeloma,
6 51 M ATTR (wild-type), cardiac involvement
7 73 M AL, cardiac, renal, splenic involvement, underlying myeloma
8 87 M ATTR (wild-type), cardiac involvement
9 50 F AL, cardiac, renal, splenic involvement
10 67 M AL, cardiac involvement
11 58 M AL, cardiac and splenic involvement, underlying myeloma
12 47 M AL, cardiac and renal involvement
13 59 M AL, cardiac, liver, renal and splenic involvement, underlying myeloma
14a 58 M AL, cardiac, liver renal and splenic involvement
15 46 F AL, cardiac involvement
16 64 M AL, cardiac, renal and splenic involvement, submandibular swelling
17 58 M AL, cardiac and renal involvement, macroglossia, underlying myeloma
a Patient underwent a second scan during the study
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Lung uptake
Lung uptake was seen in three patients on the 18F-florbetapir
half-body images (Table 2, Figs. 1a and 2f). The pattern of
uptake was different in all three patients. Patient 3 showed
distinct 18F-florbetapir uptake with a gradient across the lungs
with greater uptake in the posterior than in the anterior aspect
(unchanged on repeat imaging 8 months later), patient 7
showed intense and homogeneous uptake, and patient 9
showed heterogeneous focal uptake (corresponding to a lung
nodule). The time–activity curves (data not presented) showed
that Bnormal^ lung uptake peaked shortly after administration
and cleared rapidly, whereas in the three patients with in-
creased lung uptake, the uptake was higher and cleared very
slowly. Patient 3 had clinically suspected diffuse pulmonary
amyloidosis on high resolution CT scanning with a
ground-glass appearance. None of the patients with lung up-
take had biopsy-proven lung amyloidosis.
Liver uptake
18F-Florbetapir is excreted via the hepatobiliary system. Liver
and bile duct uptake was seen in all patients with the excreted
tracer clearing through the small bowel (Fig. 1). Figure 3c
shows time–activity curves of SUVmean in VOIs in the liver.
There was no significant correlation between 18F-florbetapir
and 123I-SAP uptake, suggesting limited utility of
18F-florbetapir for assessing the presence of amyloidosis in
the liver.
Kidney uptake
A total of nine patients had clinical renal involvement
(Table 1), six patients had kidney uptake on 123I-SAP scintig-
raphy and only two patients showed low-grade diffuse kidney
uptake of 18F-florbetapir on the late half-body images
(Table 2, Fig. 2j).
Stomach uptake
18F-Florbetapir uptake was seen in the stomach wall (Fig. 2h)
and lumen. The uptake seemed to be moving from the stom-
ach wall into the lumen on the dynamic images in 11 patients.
On late half-body images, 4 patients (24%) and 12 patients
(71%) showed 18F-florbetapir uptake in the wall of the stom-
ach and in the lumen, respectively. Uptake in both the wall and
lumen was seen in 3 patients (18%). One patient showed dif-
ferent findings on his initial and repeat scans.
Fig. 2 Transaxial 18F-florbetapir fused PET/CT images showing repre-
sentative areas of tracer uptake: a pterygoids (patient 3), b parotids (pa-
tient 2), c tongue (patient 17), d thyroid (patient 14), e subcutaneous and
pericardial fat (patient 8), f lungs (patient 7), g heart and bone marrow
(patient 2), h liver, bile ducts and stomach wall (patient 2), I liver and
spleen (patient 1), j liver, gallbladder, small bowel and kidneys (patient
13)
Eur J Nucl Med Mol Imaging
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Fat uptake
Some 18F-florbetapir uptake was seen in the fat in 12 patients
(Table 2, Fig. 2e). including subcutaneous fat (7 patients,
41%), mediastinal fat (4, 24%), and abdominal and pelvic
fat (9, 53%). In some patients this uptake was localized to
specific regions, while in others the uptake was more
widespread.
Bone marrow uptake
18F-Florbetapir uptake was seen in the bone marrow in all
patients (Table 2, Figs. 1c and 2g) and some degree of bone
marrow uptake is most likely physiological [19]. The mean
SUVmax on the half-body images was 4.2 (range 1.6–6.3;
Table 2). Three patients had bone marrow uptake on
123I-SAP scans (Table 2), and these patients had high early
SUVmean values on the 18F-florbetapir study. The signifi-
cance of this uptake is unclear. The bone marrow uptake–time
curves are shown in Fig. 3d.
Tongue uptake
18F-Florbetapir uptake was seen in the tongue in eight patients
(Table 2, Fig. 2c) with a mean SUVmax of 4.1 (range 2.8–
5.0), but of these patients only two had clinically significant
macroglossia (Table 1). Two other patients with clinical
macroglossia did not show increased 18F-florbetapir uptake.
Other head and neck uptake
Uptake was seen in other tissues in which amyloid deposits
are known to form, including the parotid glands (Fig. 2b),
thyroid (Fig. 2d) and larynx (Table 2). Most patients had
low-grade bilateral and symmetrical parotid uptake consid-
ered to be physiological, eight patients had increased parotid
uptake with an intensity suggestive of a pathological process
with a mean SUVmax of 4.3 (range 2.2–7.4; Table 2). Three
patients had increased thyroid uptake (SUVmax 4.4, 10.0 and
31.1; Table 2). Laryngeal uptake was seen in 3 patients (18%;
Table 2). Uptake was also seen in the pterygoid (Fig. 2a),
orbital and other masticating muscles (Table 2).
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Fig. 3 a Spleen uptake–time curves for all patients with the 123I-SAP
spleen scores indicated. b 18F-Florbetapir spleen retention index (SRI)
in relation to 123I-SAP spleen score. Patients with a higher 123I-SAP
spleen score can be seen to have a higher SRI. c Liver uptake–time curves
for all patients with the 123I-SAP liver score indicated (dashed lines
represent patients with liver uptake on 123I-SAP scans). d Bone marrow
uptake–time curves for all patients with the 123I-SAP bone marrow scores
indicated (dashed lines represent patients with bone marrow uptake on
123I-SAP scans)
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Repeat scans
The three patients with repeat scans showed a stable appear-
ance with all the sites of nonphysiological 18F-florbetapir up-
take on the baseline half-body images showing similar find-
ings on the repeat half-body images. The uptake–time curves
for all organs were unchanged from baseline except the curves
for the stomach and liver in patient 14. This may have been
physiological or related to diet or fasting, as patients were not
required to restrict their eating or drinking prior to the scan.
Discussion
This is the first study to provide a comprehensive description
and analysis of extracardiac sites of 18F-florbetapir uptake on
PET in patients with proven systemic amyloidosis. The most
striking and consistent finding was spleen uptake of
18F-florbetapir. This is particularly important, as 123I-SAP
scintigraphy is the only specific method for spleen imaging
and 70% of AL patients have spleen uptake on 123I-SAP im-
aging [6]. Using 123I-SAP as the gold standard, on dynamic
18F-florbetapir with a SRI cut-off value of 0.045, the sensitiv-
ity and specificity were 100%. On late half-body images sen-
sitivity was 66.7% and specificity was 100%. Importantly,
there is no clinical splenic involvement in ATTRwt and there
was no spleen uptake of 18F-florbetapir in the two patients
with ATTRwt. The higher sensitivity and specificity of
18F-florbetapir on dynamic than on late imaging suggests that
earlier imaging (around 15 min after injection) would be best
for imaging 18F-florbetapir uptake in the spleen. Since splenic
involvement is a hallmark of AL, the presence of both cardiac
and splenic involvement on 18F-florbetapir imaging could po-
tentially be used as an indicator of AL. The combination is
generally not seen in other types of amyloidosis except rare
hereditary apolipoprotein A1 amyloidosis.
The other striking finding was marked lung uptake in three
patients. There is currently no specific imaging technique for
detecting lung involvement in patients with systemic AL –
diffuse lung involvement remains one of the few areas that
are very poorly studied and understood in AL. One of the
patients with abnormal lung uptake had interstitial shadowing
on high-resolution lung CT images and was suspected to have
lung involvement. The significance of lung uptake merits fur-
ther specific study particularly in patients with proven pulmo-
nary amyloidosis, since a limitation of our study was the lack
of histological proof of lung involvement. The altered
haemodynamics in cardiac AL also raises the question about
poor tracer clearance from the lungs in patients with heart
failure since there are no data on this in other settings of heart
failure. In their recent study, Ezawa et al. [12] considered
11C-PIB lung uptake to be physiological in both patients and
controls. The pattern and intensity of uptake in their series was
very different from the one in our patient cohort. In our series,
uptake was particularly intense and diffuse in two patients and
moremoderate and heterogeneous in the third patient. None of
the other patients demonstrated any lung uptake. The differ-
ence in our findings is probably due to the use of different
tracers. Further studies investigating the ability of amyloid
tracers to detect amyloidosis lung involvement are needed to
ascertain their exact role in patient management.
Uptake in fat was identified in more than half the patients
which is not dissimilar to the proportion of patients with AL in
whom amyloid deposition can be confirmed in abdominal fat
aspirates. The uptake of 18F-florbetapir in liver was poorly
correlated with 123I-SAP scintigraphy and there was limited
kidney uptake, suggesting limited utility of 18F-florbetapir for
liver or kidney imaging.
Our results indicate that 18F-florbetapir is excreted from the
gastric wall into the gastric lumen in most patients and is then
cleared into the small bowel but at variable rates (possibly
influenced by fasting status and diet). Early gastric uptake
and clearance is likely to be physiological since similar stom-
ach activity was also seen in a dosimetry study by Joshi et al.
[19]. However, the late stomach wall uptake, noted in 24% of
patients, is likely to have been pathological. Diagnosis of gas-
trointestinal involvement in AL is mainly dependent on symp-
toms (in the absence of pathology to explain those symptoms).
18F-Florbetapir may prove useful for imaging in such patients
for diagnosis of gut amyloidosis. Ezawa et al. demonstrated a
good correlation between gastric uptake and clinical gastric
involvement (decreased gastric motility) in their series [12].
The differences between our findings and those of Ezawa et al.
may be due to the different imaging protocols used. We per-
formed a dynamic study over 60 min followed by a half-body
acquisition, and Ezawa et al. scanned their patients 30 min
after injection. There may also be differences in the results
due to the use of different tracers.
Although few patients showed marrow uptake on 123I-SAP
scintigraphy in the current series, the agreement between the
two tracers was striking. Bonemarrow uptake of 18F-florbetapir
occurs in normal controls [19] and hence its utility for bone
marrow imaging remains unclear, although patients with higher
bone marrow uptake are likely to have pathological bone in-
volvement. Such uptake in a patient with amyloidosis may
support a diagnosis of AL as marrow uptake is not seen (on
123I-SAP scintigraphy) in any other amyloid type.
Three patients with AL had repeat 18F-florbetapir imaging.
At the time of their initial imaging, one of these patients was
treatment-naive and subsequently went on to have chemother-
apy, one was receiving the first cycle of chemotherapy and one
had achieved a complete response with chemotherapy. All
three patients were in a haematological complete response at
the time of repeat imaging. Despite achievement of a haema-
tological response, there were no differences in the distribu-
tion and intensity of uptake between initial and repeat
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imaging. This may have been due to the relatively short time
between the baseline and follow-up scans.
Imaging amyloid deposits outside the heart has remained
challenging. Recently, most imaging methods such as cardiac
MRI and 99mTc-DPD/PYP have focused on cardiac amyloid
detection. 123I-SAP scintigraphy is used in routine clinical prac-
tice at the UKNational Amyloidosis Centre for in vivo imaging
of amyloid deposits and is the only method that is clinically
validated for this purpose. The uptake of 123I-SAP correlates
with the amount of amyloid [6] with a 90% sensitivity in am-
yloid A amyloidosis and AL [20]. The main limitation of the
technique is that it is available at only two centres worldwide
(UK National Amyloidosis Centre and Groningen University)
because of its technical complexity. The other limitation is that
123I-SAP scintigraphy images the liver, spleen, kidneys and
bone, but cannot image the hollow viscera, other soft tissues
and heart. Recently, extracardiac uptake of PET tracers
(18F-florbetapir, 18F-florbetaben and 11C-PIB) has been de-
scribed in a few case reports: in the larynx [21], cerebral
amyloidoma [22], in the kidneys in ALECT2 type of amyloid-
osis [23] and in the brain [24]. The only systematic study of
extracardiac uptake has recently been published [12].
Half-body images were acquired 30 min after 11C-PiB injection
and showed abnormal tracer uptake in the spleen, stomach, lach-
rymal glands, submandibular glands, sublingual glands, lymph
nodes, brain, scalp, extraocular muscles, nasal mucosa, pharynx,
tongue and nuchal muscles, but most patients were asymptom-
atic. Ezawa et al. also noted physiological tracer uptake in the
urinary tract (kidney, renal pelvis, ureter and bladder) and
enterohepatic circulatory system (liver, gallbladder, bile duct
and small intestine). Our findings with 18F-florbetapir PET im-
aging are in broad agreement with the results of 11C-PiB PET
imaging. The main advantage of 18F-florbetapir over 11C-PiB
PET with regard to potential routine clinical implementation is
its longer half-life, with no need for an on-site cyclotron and with
commercially available solutions for supply and delivery already
available in most of Europe and North America.
One of the main limitations of the study was that there was
no biopsy proof for every site noted to have abnormal
18F-florbetapir uptake. This was not part of the protocol and,
due to potential risks, not ethically acceptable in the absence
of a specific clinical indication. The other limitation was that
this study was limited to cardiac patients (mainly because the
study was originally designed to study cardiac amyloidosis)
and only patients with AL and ATTRwt were included.
Investigation of patients with a wider range of amyloid types
and organ involvement is needed to understand physiological
and abnormal 18F-florbetapir uptake.
In summary, there are a limited number of techniques for
imaging extracardiac amyloid deposits. 123I-SAP, the gold
standard for imaging systemic amyloidosis, has major limita-
tions (it is only available in two centres worldwide, it requires
the use of human plasma-derived SAP protein, and the
preparation of the tracer is complex). 18F-Florbetapir (and
other similar tracers) does not have the same limitations and
has the great advantage that it is already commercially avail-
able worldwide and can be ordered by any appropriately
equipped department. Scanning is easy with a half-body scan
acquired in less than 30 min as early as 15 min after injection.
PETcameras also have better resolution than gamma cameras,
along with the possibility of acquiring dynamic scans on
cross-sectional images. The combination of heart and spleen
uptake of 18F-florbetapir may be a specific signature of AL.
With its very high cardiac specificity that has already been
reported and the additional imaging of extracardiac deposits,
18F-florbetapir has the potential to become the main tracer for
the diagnosis of systemic amyloidosis. Its role in monitoring
disease remains to be clarified, as we did not see any changes
on repeat imaging following successful treatment. Large stud-
ies in unselected patients with AL are urgently needed to con-
firm these findings.
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